Over 20 companies are racing to develop treatments for myotonic dystrophy, a rare muscle disorder.

Over 20 pharmaceutical companies are actively researching treatments for myotonic dystrophy, a rare muscle disorder with no current FDA-approved therapies. This surge in development is driving market growth and attracting more funding and partnerships. Key companies like Avidity Biosciences, Dyne Therapeutics, and Vertex Pharmaceuticals are advancing various therapies through clinical trials, with some receiving promising designations from the FDA.

November 27, 2024
3 Articles